STAT Plus: New type of checkpoint inhibitor offers early promise against tumors, but will it last?
ADOBE
The worry is that the drug will later fall short, like similar efforts to develop immunotherapies for the two-thirds of cancer patients they now don't help.
.png)
No hay comentarios:
Publicar un comentario